Downstream mechanistic pathways diverge, manifesting as metabolic and mitochondrial collapse in MYCN-amplified neuroblastoma, whereas transcriptional and translational repression predominates in MYC family-driven medulloblastoma. The gene discussed is MYCN; the disease is neuroblastoma.